Table 1.
Baseline Characteristics of Study Cohorts
| Variable | Cohort 1 (N = 39) | Cohort 2 (N = 13) | Combined (N=52) |
|---|---|---|---|
|
| |||
| Age (years) | 16.5 ± 1.6 | 16.5 ± 1.6 | 16.5 ± 1.6 |
|
| |||
| Sex (M/F) | 10 (26%)/29 (74%) | 3 (23%)/10 (77%) | 13 (25%)/39 (75%) |
|
| |||
| Race | |||
| White | 28 (72%) | 11 (85%) | 39 (75%) |
| Other | 11 (28%) | 2 (15%) | 13 (25%) |
|
| |||
| Height (cm) | 168.7 ± 11.6 | 168.3 ± 7.3 | 168.6 ± 10.6 |
|
| |||
| Weight (kg) | 146.4 ± 35.8 | 168.7 ± 22.9 | 151.7 ± 34.4 |
|
| |||
| BMI (kg/m2) | 51.0 ± 9.6 | 58.7 ± 6.8 | 52.8 ± 9.6 |
|
| |||
| Co-morbidities | |||
| Sleep Apnea | 22 (56%) | 9 (69%) | 31 (60%) |
| Hypertension | 16 (41%) | 3 (23%) | 19 (37%) |
| Type 2 Diabetes | 5 (13%) | 1 (8%) | 6 (12%) |
| Polycystic Ovary | 6 (15%) | 3 (23%) | 9 (17%) |
| Syndrome | |||
| Dyslipidemia | 33 (85%) | 8 (62%) | 41 (79%) |
|
| |||
| Surgery Type | |||
| RYGB | 19 (49%) | 13 (100%) | 32 (62%) |
| VSG | 20 (51%) | 0 (0%) | 20 (38%) |
|
| |||
| Glucose (mg/dL) | 74.6 ± 10.9 | 94.0 ± 8.3 | 79.2 ± 13.2 |
|
| |||
| Insulin (μU/mL) | 21.3 ± 8.5 | 15.2 ± 11.5 | 21.3 ± 9.5 |
|
| |||
| HOMA-IR | 4.0 ± 1.8 | 4.9 ± 2.8 | 4.2 ± 2.1 |
|
| |||
| IL-6 (pg/mL) | 2.3 ± 3.4 | 1.7 ± 0.9 | 2.1 ± 1.6 |
|
| |||
| TNF-α (pg/mL) | 3.1 ± 1.3 | 1.3 ± 0.9 | 2.7 ± 1.5 |
|
| |||
| Leptin (ng/mL) | 178 ± 224 | 93 ± 31 | 158 ± 199 |
|
| |||
| MCP-1 (pg/mL) | 198.1 ± 88.6 | 216.8 ± 103.4 | 201.7 ± 92.3 |
|
| |||
| Resistin ng/mL) | 7.0 ± 2.6 | 7.8 ± 3.4 | 7.2 ± 2.8 |
|
| |||
| OxLDL (U/L) | 41.6 ± 11.6 | 34.0 ± 26.3 | 39.8 ± 16.7 |
|
| |||
| Adiponectin (μg/mL) | 5.4 ± 2.4 | 6.1 ± 2.9 | 5.4 ± 2.3 |
Data are presented as mean ± standard deviation or number and percent. RYGB = laparoscopic roux en Y gastric bypass; VSG = vertical sleeve gastrectomy